TCGA-CV-6433-01A-11R-1686-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.600
- G2M_CHECKPOINT+0.470
- ALLOGRAFT_REJECTION+0.410
- DNA_REPAIR+0.400
- OXIDATIVE_PHOSPHORYLATION+0.330
- MYC_TARGETS_V1+0.310
- SPERMATOGENESIS+0.300
- INTERFERON_GAMMA_RESPONSE+0.270
- INTERFERON_ALPHA_RESPONSE+0.250
- IL6_JAK_STAT3_SIGNALING+0.240
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.450
- ANGIOGENESIS-0.350
- MYOGENESIS-0.330
- NOTCH_SIGNALING-0.310
- HEDGEHOG_SIGNALING-0.280
- UV_RESPONSE_DN-0.280
- COAGULATION-0.250
- ESTROGEN_RESPONSE_EARLY-0.240
- APICAL_JUNCTION-0.230
- KRAS_SIGNALING_UP-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-KU-A6H7-01A-11R-A31N-07 | — | — | 0.864 |
| 2 | TCGA-18-3410-01A-01R-0980-07 | — | cohortSQ1 | 0.852 |
| 3 | KG1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.850 |
| 4 | SRR8518289 | — | E | 0.845 |
| 5 | 58c2404d-b213-4a7f-a8fc-11081a88091b | — | — | 0.844 |
| 6 | TCGA-C8-A1HM-01A-12R-A137-07 | — | C | 0.836 |
| 7 | SRR26320066 | — | — | 0.836 |
| 8 | SRR8518297 | — | E | 0.836 |
| 9 | c63f3f74-14fa-4a9e-9925-30b0f5da7dd9 | — | — | 0.830 |
| 10 | 213f702a-56fd-4ab0-940c-a71e4e01b6f8 | — | — | 0.829 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.600 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.470 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.410 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.400 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.330 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.310 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.300 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.270 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.250 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.240 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.170 | Inavolisib | — uncovered |
| PEROXISOME | 0.160 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.120 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.110 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.110 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.070 | Inavolisib | — uncovered |
| APOPTOSIS | 0.070 | Idelalisib | — uncovered |
| COMPLEMENT | 0.050 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.040 | Idelalisib | — uncovered |